Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Citi
Boehringer Ingelheim
Federal Trade Commission
Julphar
US Army
Colorcon
Cipla
Moodys

Generated: May 24, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,964,202

« Back to Dashboard

Which drugs does patent 7,964,202 protect, and when does it expire?

Patent 7,964,202 protects EPIDUO and is included in one NDA.

This patent has thirty patent family members in twenty-two countries.
Summary for Patent: 7,964,202
Title:Method for treatment of common acne
Abstract: Dermatological/cosmetic compositions suited for preventing or treating cell differentiation and/or proliferation and/or keratinization disorders, including preventing or treating common acne, comprise, in a physiologically acceptable medium, (i) at least one dispersed retinoid, (ii) dispersed benzoyl peroxide, in free or encapsulated form, and (iii) at least one pH-independent gelling agent, said dermatological/cosmetic composition having physical stability without loss of viscosity over time at a temperature ranging from 4.degree. C. to 40.degree. C., said dermatological/cosmetic composition having a stable flow threshold over time as measured by viscosity measurements for rheograms which measure a shear stress .tau. for a given rate gradient .gamma. and which measure a rate gradient .gamma. for a given shear stress .tau., the yield value (.tau.0) being extrapolated visually or by calculation.
Inventor(s): Orsoni; Sandrine (Mandelieu, FR), Willcox; Nathalie (Le Rouret, FR)
Assignee: Galderma Research & Development, S.N.C. (FR)
Application Number:12/076,859
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 7,964,202

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Galderma Labs Lp EPIDUO adapalene; benzoyl peroxide GEL;TOPICAL 022320-001 Dec 8, 2008 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y TREATMENT OF ACNE ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,964,202

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France01 16747Dec 21, 2001

Non-Orange Book US Patents Family Members for Patent 7,964,202

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,241,649 Dermatological/cosmetic gels comprising at least one retinoid and/or retinoid salt and benzoyl peroxide ➤ Sign Up
7,820,186 Gel composition for once-daily treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt ➤ Sign Up
9,814,690 Gel composition for treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt ➤ Sign Up
8,936,800 Gel composition for treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Express Scripts
Farmers Insurance
Cipla
Johnson and Johnson
UBS
Harvard Business School
Dow
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.